Identification and characterization of linezolid-resistant cfr-positive staphylococcus aureus USA300 Isolates from a new york city medical center

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 11, 2014, Pages 6949-6952

  Locke, Jeffrey B ^a   Zuill, Douglas E ^a   Scharn, Caitlyn R ^c   Deane, Jennifer ^b   Sahm, Daniel F ^b   Goering, Richard V ^c   Jenkins, Stephen G ^d   Shaw, Karen J ^a  

^a Trius Therapeutics Inc   (United States)

^b Eurofins Medinet Inc   (Germany)

^c CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; CLINDAMYCIN; DAPTOMYCIN; ERYTHROMYCIN; FLORFENICOL; GENTAMICIN; LINEZOLID; OXACILLIN; TEDIZOLID; TETRACYCLINE; TIAMULIN; TRIMETHOPRIM; VANCOMYCIN; ACETAMIDE DERIVATIVE; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; CFR PROTEIN, STAPHYLOCOCCUS AUREUS; DITERPENE; ORGANOPHOSPHATE; OXAZOLE DERIVATIVE; OXAZOLIDINONE DERIVATIVE; THIAMPHENICOL;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIUM IDENTIFICATION; BACTERIUM TRANSFORMATION; CFR GENE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; NUCLEOTIDE SEQUENCE; PLASMID; SEQUENCE ANALYSIS; UNITED STATES; ANALOGS AND DERIVATIVES; DRUG EFFECTS; GENE TRANSFER; GENETICS; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MOLECULAR GENETICS; MULTIDRUG RESISTANCE; NEW YORK; STAPHYLOCOCCAL INFECTIONS;

ACETAMIDES; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; CLINDAMYCIN; DITERPENES; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GENE TRANSFER TECHNIQUES; HUMANS; LINEZOLID; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; NEW YORK; ORGANOPHOSPHATES; OXAZOLES; OXAZOLIDINONES; PLASMIDS; STAPHYLOCOCCAL INFECTIONS; THIAMPHENICOL;

EID: 84908596733     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03380-14     Document Type: Article

References (31)

1. Toh SM, Xiong L, Arias CA, Villegas MV, Lolans K, Quinn J, Mankin AS. 2007. Acquisition of a natural resistance gene renders a clinical strain of methicillin-resistant Staphylococcus aureus resistant to the synthetic antibiotic linezolid. Mol. Microbiol. 64:1506-1514. http://dx.doi.org/10.1111/j.1365-2958.2007.05744.x.
2. Long KS, Poehlsgaard J, Kehrenberg C, Schwarz S, Vester B. 2006. The cfr rRNA methyltransferase confers resistance to phenicols, lincosamides, oxazolidinones, pleuromutilins, and streptogramin A antibiotics. Antimicrob. Agents Chemother. 50:2500-2505. http://dx.doi.org/10.1128/AAC .00131-06.
3. Smith LK, Mankin AS. 2008. Transcriptional and translational control of the mlr operon, which confers resistance to seven classes of protein synthesis inhibitors. Antimicrob. Agents Chemother. 52:1703-1712. http://dx.doi.org/10.1128/AAC.01583-07.
4. Shen J, Wang Y, Schwarz S. 2013. Presence and dissemination of the multiresistance gene cfr in Gram-positive and Gram-negative bacteria. J. Antimicrob. Chemother. 68:1697-1706. http://dx.doi.org/10.1093/jac/dkt092.
5. Ross JE, Mendes RE, Flamm RK, Jones RN. 2012. Abstr. 52nd Intersci. Conf. Antimicrob. Agents Chemother., abstr C2-139.
6. Mendes RE, Deshpande LM, Castanheira M, Dipersio J, Saubolle M, Jones RN. 2008. First report of cfr-mediated resistance to linezolid in human staphylococcal clinical isolates recovered in the United States. Antimicrob. Agents Chemother. 52:2244-2246. http://dx.doi.org/10.1128/AAC.00231-08.
7. Flamm RK, Farrell DJ, Mendes RE, Ross JE, Sader HS, Jones RN. 2012. LEADER surveillance program results for 2010: an activity and spectrum analysis of linezolid using 6801 clinical isolates from the United States (61 medical centers). Diagn. Microbiol. Infect. Dis. 74:54-61. http://dx.doi.org/10.1016/j.diagmicrobio.2012.05.012.
8. Farrell DJ, Mendes RE, Ross JE, Sader HS, Jones RN. 2011. LEADER Program results for 2009: an activity and spectrum analysis of linezolid using 6,414 clinical isolates from 56 medical centers in the United States. Antimicrob. Agents Chemother. 55:3684-3690. http://dx.doi.org/10.1128/AAC.01729-10.
9. Locke JB, Zuill DE, Sahm DF, Deane J, Denys GA, Shaw KJ. 2013. Abstr. 23rd Eur. Congr. Clin. Microbiol. Infect. Dis., abstr O 449.
10. Ross JE, Deshpande LM, Castanheira M, Jones RN. 2011. Abstr. 111th Gen. Meet. Am. Soc. Microbiol., abstr A-4.
11. Streit JM, Ross JE, Mendes RE, Flamm RK, Jones RN, Hogan PA. 2013. Abstr. IDWeek 2013 Infect. Dis. Soc. Am., abstr 737.
12. Farrell DJ, Mendes RE, Ross JE, Jones RN. 2009. Linezolid surveillance program results for 2008 (LEADER Program for 2008). Diagn. Microbiol. Infect. Dis. 65:392-403. http://dx.doi.org/10.1016/j.diagmicrobio.2009 .10.011.
13. Mendes RE, Flamm RK, Hogan PA, Ross JE, Jones RN. 2014. Summary of linezolid activity and resistance mechanisms detected during the 2012 LEADER Surveillance Program for the United States. Antimicrob. Agents Chemother. 58:1243-1247. http://dx.doi.org/10.1128/AAC.02112-13.
14. Shaw KJ, Barbachyn MR. 2011. The oxazolidinones: past, present, and future. Ann. N. Y. Acad. Sci. 1241:48-70. http://dx.doi.org/10.1111/j.1749-6632.2011.06330.x.
15. Long KS, Vester B. 2012. Resistance to linezolid caused by modifications at its binding site on the ribosome. Antimicrob. Agents Chemother. 56: 603-612. http://dx.doi.org/10.1128/AAC.05702-11.
16. Im WB, Choi SH, Park JY, Finn J, Yoon SH. 2011. Discovery of torezolid as a novel 5-hydroxymethyl-oxazolidinone antibacterial agent. Eur. J. Med. Chem. 46:1027-1039. http://dx.doi.org/10.1016/j.ejmech.2011.01 .014.
17. Locke JB, Finn J, Hilgers M, Morales G, Rahawi S, Kedar GC, Picazo JJ, Im W, Shaw KJ, Stein JL. 2010. Structure-activity relationships of diverse oxazolidinones for linezolid-resistant Staphylococcus aureus strains possessing the cfr methyltransferase gene or ribosomal mutations. Antimicrob. Agents Chemother. 54:5337-5343. http://dx.doi.org/10.1128/AAC .00663-10.
18. Shaw KJ, Poppe S, Schaadt R, Brown-Driver V, Finn J, Pillar CM, Shinabarger D, Zurenko G. 2008. In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strains. Antimicrob. Agents Chemother. 52:4442-4447. http://dx.doi.org/10.1128/AAC.00859-08.
19. Locke JB, Zuill DE, Scharn CR, Deane J, Sahm DF, Jenkins SG, Goering RV, Shaw KJ. 2013. Abstr. 53rd Intersci. Conf. Antimicrob. Agents Chemother., abstr C1-517.
20. Deane J, Opiela C, Shah D, Shaw K, Locke J, Sahm D. 2013. Abstr. 53rd Intersci. Conf. Antimicrob. Agents Chemother., abstr C2-090.
21. Locke JB, Hilgers M, Shaw KJ. 2009. Novel ribosomal mutations in Staphylococcus aureus strains identified through selection with the oxazolidinones linezolid and torezolid (TR-700). Antimicrob. Agents Chemother. 53:5265-5274. http://dx.doi.org/10.1128/AAC.00871-09.
22. CLSI. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard-9th ed, vol 32, no. 2. CLSI document M07-A9. Clinical and Laboratory Standards Institute, Wayne, PA.
23. Schaadt R, Sweeney D, Shinabarger D, Zurenko G. 2009. The in vitro activity of TR-700, the active ingredient of the antibacterial prodrug TR-701, a novel oxazolidinone antibacterial agent. Antimicrob. Agents Chemother. 53:3236-3239. http://dx.doi.org/10.1128/AAC.00228-09.
24. Goering RV, Ribot EM, Gerner-Smidt P. 2011. Pulsed field gel electrophoresis: laboratory and epidemiologic considerations for interpretation of data, p 167-177. In Persing DH, Tenover FC, Nolte FS, Hayden RT, van Belkum A (ed), Molecular microbiology: diagnostic principles and practice, 2nd ed. ASM Press, Washington, DC.
25. Locke JB, Rahawi S, Lamarre J, Mankin AS, Shaw KJ. 2012. Genetic environment and stability of cfr in methicillin-resistant Staphylococcus aureus CM05. Antimicrob. Agents Chemother. 56:332-340. http://dx.doi.org/10.1128/AAC.05420-11.
26. Schenk S, Laddaga RA. 1992. Improved method for electroporation of Staphylococcus aureus. FEMS Microbiol. Lett. 73:133-138.
27. Locke JB, Morales G, Hilgers M, Kedar GC, Rahawi S, Picazo JJ, Shaw KJ, Stein JL. 2010. Elevated linezolid resistance in clinical cfr-positive Staphylococcus aureus isolates is associated with co-occurring mutations in ribosomal protein L3. Antimicrob. Agents Chemother. 54:5352-5355. http://dx.doi.org/10.1128/AAC.00714-10.
28. Karlyshev AV, Pallen MJ, Wren BW. 2000. Single-primer PCR procedure for rapid identification of transposon insertion sites. Biotechniques 28:1078, 1080, 1082.
29. Kehrenberg C, Schwarz S. 2006. Distribution of florfenicol resistance genes fexA and cfr among chloramphenicol-resistant Staphylococcus isolates. Antimicrob. Agents Chemother. 50:1156-1163. http://dx.doi.org/10.1128/AAC.50.4.1156-1163.2006.
30. Mendes RE, Deshpande LM, Bonilla HF, Schwarz S, Huband MD, Jones RN, Quinn JP. 2013. Dissemination of a pSCFS3-like cfr-carrying plasmid in Staphylococcus aureus and Staphylococcus epidermidis clinical isolates recovered from hospitals in Ohio. Antimicrob. Agents Chemother. 57:2923-2928. http://dx.doi.org/10.1128/AAC.00071-13.
31. LaMarre JM, Locke JB, Shaw KJ, Mankin AS. 2011. Low fitness cost of the multidrug resistance gene cfr. Antimicrob. Agents Chemother. 55: 3714-3719. http://dx.doi.org/10.1128/AAC.00153-11.